Cervical cancer prevention: New tools and old barriers

Isabel C. Scarinci, Francisco A Garcia, Erin Kobetz, Edward E. Partridge, Heather M. Brandt, Maria C. Bell, Mark Dignan, Grace X. Ma, Jane L. Daye, Philip E. Castle

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Cervical cancer is the second most common female tumor worldwide, and its incidence is disproportionately high (>80%) in the developing world. In the United States, in which Papanicolaou (Pap) tests have reduced the annual incidence to approximately 11,000 cervical cancers, >60% of cases are reported to occur in medically underserved populations as part of a complex of diseases linked to poverty, race/ethnicity, and/or health disparities. Because carcinogenic human papillomavirus (HPV) infections cause virtually all cervical cancer, 2 new approaches for cervical cancer prevention have emerged: 1) HPV vaccination to prevent infections in younger women (aged ≤18 years) and 2) carcinogenic HPV detection in older women (aged ≥30 years). Together, HPV vaccination and testing, if used in an age-appropriate manner, have the potential to transform cervical cancer prevention, particularly among underserved populations. Nevertheless, significant barriers of access, acceptability, and adoption to any cervical cancer prevention strategy remain. Without understanding and addressing these obstacles, these promising new tools for cervical cancer prevention may be futile. In the current study, the delivery of cervical cancer prevention strategies to these US populations that experience a high cervical cancer burden (African-American women in South Carolina, Alabama, and Mississippi; Haitian immigrant women in Miami; Hispanic women in the US-Mexico Border; Sioux/Native American women in the Northern Plains; white women in the Appalachia; and Vietnamese-American women in Pennsylvania and New Jersey) is reviewed. The goal was to inform future research and outreach efforts to reduce the burden of cervical cancer in underserved populations.

Original languageEnglish (US)
Pages (from-to)2531-2542
Number of pages12
JournalCancer
Volume116
Issue number11
DOIs
StatePublished - Jun 1 2010

Fingerprint

Uterine Cervical Neoplasms
Vulnerable Populations
Vaccination
Appalachian Region
Mississippi
Papanicolaou Test
Papillomavirus Infections
Asian Americans
North American Indians
Incidence
Poverty
Mexico
Hispanic Americans
African Americans
Health
Infection

Keywords

  • Cervical cancer
  • Cervical cancer prevention
  • Human papillomavirus testing
  • Human papillomavirus vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Scarinci, I. C., Garcia, F. A., Kobetz, E., Partridge, E. E., Brandt, H. M., Bell, M. C., ... Castle, P. E. (2010). Cervical cancer prevention: New tools and old barriers. Cancer, 116(11), 2531-2542. https://doi.org/10.1002/cncr.25065

Cervical cancer prevention : New tools and old barriers. / Scarinci, Isabel C.; Garcia, Francisco A; Kobetz, Erin; Partridge, Edward E.; Brandt, Heather M.; Bell, Maria C.; Dignan, Mark; Ma, Grace X.; Daye, Jane L.; Castle, Philip E.

In: Cancer, Vol. 116, No. 11, 01.06.2010, p. 2531-2542.

Research output: Contribution to journalArticle

Scarinci, IC, Garcia, FA, Kobetz, E, Partridge, EE, Brandt, HM, Bell, MC, Dignan, M, Ma, GX, Daye, JL & Castle, PE 2010, 'Cervical cancer prevention: New tools and old barriers', Cancer, vol. 116, no. 11, pp. 2531-2542. https://doi.org/10.1002/cncr.25065
Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC et al. Cervical cancer prevention: New tools and old barriers. Cancer. 2010 Jun 1;116(11):2531-2542. https://doi.org/10.1002/cncr.25065
Scarinci, Isabel C. ; Garcia, Francisco A ; Kobetz, Erin ; Partridge, Edward E. ; Brandt, Heather M. ; Bell, Maria C. ; Dignan, Mark ; Ma, Grace X. ; Daye, Jane L. ; Castle, Philip E. / Cervical cancer prevention : New tools and old barriers. In: Cancer. 2010 ; Vol. 116, No. 11. pp. 2531-2542.
@article{12ee510ab84e411892c0b7c94e545313,
title = "Cervical cancer prevention: New tools and old barriers",
abstract = "Cervical cancer is the second most common female tumor worldwide, and its incidence is disproportionately high (>80{\%}) in the developing world. In the United States, in which Papanicolaou (Pap) tests have reduced the annual incidence to approximately 11,000 cervical cancers, >60{\%} of cases are reported to occur in medically underserved populations as part of a complex of diseases linked to poverty, race/ethnicity, and/or health disparities. Because carcinogenic human papillomavirus (HPV) infections cause virtually all cervical cancer, 2 new approaches for cervical cancer prevention have emerged: 1) HPV vaccination to prevent infections in younger women (aged ≤18 years) and 2) carcinogenic HPV detection in older women (aged ≥30 years). Together, HPV vaccination and testing, if used in an age-appropriate manner, have the potential to transform cervical cancer prevention, particularly among underserved populations. Nevertheless, significant barriers of access, acceptability, and adoption to any cervical cancer prevention strategy remain. Without understanding and addressing these obstacles, these promising new tools for cervical cancer prevention may be futile. In the current study, the delivery of cervical cancer prevention strategies to these US populations that experience a high cervical cancer burden (African-American women in South Carolina, Alabama, and Mississippi; Haitian immigrant women in Miami; Hispanic women in the US-Mexico Border; Sioux/Native American women in the Northern Plains; white women in the Appalachia; and Vietnamese-American women in Pennsylvania and New Jersey) is reviewed. The goal was to inform future research and outreach efforts to reduce the burden of cervical cancer in underserved populations.",
keywords = "Cervical cancer, Cervical cancer prevention, Human papillomavirus testing, Human papillomavirus vaccination",
author = "Scarinci, {Isabel C.} and Garcia, {Francisco A} and Erin Kobetz and Partridge, {Edward E.} and Brandt, {Heather M.} and Bell, {Maria C.} and Mark Dignan and Ma, {Grace X.} and Daye, {Jane L.} and Castle, {Philip E.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1002/cncr.25065",
language = "English (US)",
volume = "116",
pages = "2531--2542",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Cervical cancer prevention

T2 - New tools and old barriers

AU - Scarinci, Isabel C.

AU - Garcia, Francisco A

AU - Kobetz, Erin

AU - Partridge, Edward E.

AU - Brandt, Heather M.

AU - Bell, Maria C.

AU - Dignan, Mark

AU - Ma, Grace X.

AU - Daye, Jane L.

AU - Castle, Philip E.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Cervical cancer is the second most common female tumor worldwide, and its incidence is disproportionately high (>80%) in the developing world. In the United States, in which Papanicolaou (Pap) tests have reduced the annual incidence to approximately 11,000 cervical cancers, >60% of cases are reported to occur in medically underserved populations as part of a complex of diseases linked to poverty, race/ethnicity, and/or health disparities. Because carcinogenic human papillomavirus (HPV) infections cause virtually all cervical cancer, 2 new approaches for cervical cancer prevention have emerged: 1) HPV vaccination to prevent infections in younger women (aged ≤18 years) and 2) carcinogenic HPV detection in older women (aged ≥30 years). Together, HPV vaccination and testing, if used in an age-appropriate manner, have the potential to transform cervical cancer prevention, particularly among underserved populations. Nevertheless, significant barriers of access, acceptability, and adoption to any cervical cancer prevention strategy remain. Without understanding and addressing these obstacles, these promising new tools for cervical cancer prevention may be futile. In the current study, the delivery of cervical cancer prevention strategies to these US populations that experience a high cervical cancer burden (African-American women in South Carolina, Alabama, and Mississippi; Haitian immigrant women in Miami; Hispanic women in the US-Mexico Border; Sioux/Native American women in the Northern Plains; white women in the Appalachia; and Vietnamese-American women in Pennsylvania and New Jersey) is reviewed. The goal was to inform future research and outreach efforts to reduce the burden of cervical cancer in underserved populations.

AB - Cervical cancer is the second most common female tumor worldwide, and its incidence is disproportionately high (>80%) in the developing world. In the United States, in which Papanicolaou (Pap) tests have reduced the annual incidence to approximately 11,000 cervical cancers, >60% of cases are reported to occur in medically underserved populations as part of a complex of diseases linked to poverty, race/ethnicity, and/or health disparities. Because carcinogenic human papillomavirus (HPV) infections cause virtually all cervical cancer, 2 new approaches for cervical cancer prevention have emerged: 1) HPV vaccination to prevent infections in younger women (aged ≤18 years) and 2) carcinogenic HPV detection in older women (aged ≥30 years). Together, HPV vaccination and testing, if used in an age-appropriate manner, have the potential to transform cervical cancer prevention, particularly among underserved populations. Nevertheless, significant barriers of access, acceptability, and adoption to any cervical cancer prevention strategy remain. Without understanding and addressing these obstacles, these promising new tools for cervical cancer prevention may be futile. In the current study, the delivery of cervical cancer prevention strategies to these US populations that experience a high cervical cancer burden (African-American women in South Carolina, Alabama, and Mississippi; Haitian immigrant women in Miami; Hispanic women in the US-Mexico Border; Sioux/Native American women in the Northern Plains; white women in the Appalachia; and Vietnamese-American women in Pennsylvania and New Jersey) is reviewed. The goal was to inform future research and outreach efforts to reduce the burden of cervical cancer in underserved populations.

KW - Cervical cancer

KW - Cervical cancer prevention

KW - Human papillomavirus testing

KW - Human papillomavirus vaccination

UR - http://www.scopus.com/inward/record.url?scp=77952837934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952837934&partnerID=8YFLogxK

U2 - 10.1002/cncr.25065

DO - 10.1002/cncr.25065

M3 - Article

C2 - 20310056

AN - SCOPUS:77952837934

VL - 116

SP - 2531

EP - 2542

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -